Tavanta Therapeutics Ltd. has a balanced approach to discovery and product development by (i) enhancing the clinical performance of established molecules and (ii) synthesizing novel small molecules and therapeutic peptides.
The present invention is an ultra-compact capillary electrophoresis (CE) device that can operate both independently and in connection with any mass spectrometer (MS) using a product-specific adapter that can be mounted on the CE device.
The current novel molecular DNA cloning procedure – during which a given DNA fragment (DNA stretch subjected to cloning, also called “insert”) aimed to be multiplied is introduced into a vector DNA (“vehicle”) without using in vitro added enzymes such as restriction endonucleases, ligases, DNA polymerases and 5′ exonucleases – is particularly suitable for generating novel DNA constructs in a relatively fast and cost-effective way, as it performs DNA cloning without using in vitro added enzymes.
Danubia Wins First Place of the Companies For The Future Award 2024
TRADEMARK PROTECTION OF A COLOUR AGAINST THE SHADE OF THE SAME COLOUR ‘MILKA’
REIMBURSEMENT OF ENRICHMENT ACHIEVED BY TRADEMARK INFRINGEMENT
Measuring and reflecting the utilization of research results in university rankings
NOTICE OF TERMINATION FOR A LICENSE AGREEMENT